Laser Artery Disease Therapy: FDA approves next-gen laser atherectomy catheter

Feb. 17, 2016
Spectranetics (Colorado Springs, CO) has received FDA 510(k) clearance for its Turbo-Power laser atherectomy catheter to treat in-stent restenosis (ISR).

Spectranetics (Colorado Springs, CO) has received FDA 510(k) clearance for its Turbo-Power laser atherectomy catheter to treat in-stent restenosis (ISR). The company notes that laser atherectomy is driving a new standard of care for treatment of coronary artery disease, with improved clinical outcomes. The tool uses vaporizing technology to maximize luminal gain-it debulks the lesion in a single step and offers remote automatic rotation for precise directional control.

About the Author

Barbara Gefvert | Editor-in-Chief, BioOptics World (2008-2020)

Barbara G. Gefvert has been a science and technology editor and writer since 1987, and served as editor in chief on multiple publications, including Sensors magazine for nearly a decade.

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!